CTTI In the News

Collaboration and Transparency Key to More Effective Clinical Research

Much of the credit for improving the quality and efficiency of clinical trials in recent years goes to joint reform initiatives and greater disclosure of regulatory decisions and study results. Bioresearch sponsors are listing more studies on the ClinicalTrials.gov website, although the record is weaker for timely disclosure of research results for newly approved medical products. Under pressure to share more research data to avoid repeated errors and waste, biopharma companies also are providing qualified experts with access to confidential studies. And some sponsors are pledging to publish new research reports only in open access journals.

Source: Applied Clinical Trials

CTTI: Transforming clinical trials is going to take continued dedication, collaboration, and innovation

Last week CTTI and industry professionals gathered to celebrate the initiative's 10-year anniversary. To learn more about some of the key projects completed and challenges faced over the last decade - and what to expect from the next 10 years - we caught up with CTTI Executive Director Pamela Tenaerts. 

Source: Outsourcing-pharma.com

More Streamlined Clinical Research Arises from Collaborative Effort

Leaders of the biomedical research community recently celebrated progress over the last decade in devising strategies to improve the quality and efficiency of clinical trials. The 10th anniversary of the Clinical Trials Transformative Initiative (CTTI) last week provided an opportunity for FDA officials to join with study sponsors and research experts to examine the policy achievements and plans for future efforts of this multi-faceted initiative.

Source: Applied Clinical Trials

CTTI: Instituting Quality Measures Early in Trial Design Pays Off in the Long Run

At a symposium marking the Clinical Trials Transformation Initiative’s 10th anniversary, industry and regulatory discussed the progress made by its Quality by Design initiative and the additional work needed to encourage the research industry to be more focused on trial quality and efficiency.

Source: CenterWatch

CTTI Recommendations Look to Lure ‘One and Done’ Investigators Back into the Fold

Nearly half of all so-called “one and done” principal investigators who retreat from clinical research after conducting a single study want back in if they can find resources and advice to help on their second attempt, according to findings from a new Clinical Trials Transformation Initiative (CTTI) survey and recommendations project.

Source: ACRP Blog

CTTI suggests ways to prevent ‘one and done’ syndrome in trial investigators

It can be seriously disruptive when the site investigator for your trial leaves or decides to step down, but new recommendations from the Clinical Trials Transformation Initiative (CTTI) aim to mitigate that risk.

Source: FierceBiotech

How to reduce clinical trial site investigator turnover

CTTI has released new recommendations that can be implemented by sponsors, CROs, and others, in order to decrease the number of ‘one and done’ clinical trial site investigators.

Source: Outsourcing-pharma.com

Proactive pregnancy testing planning to improve safety, efficacy of clinical trials

CTTI's new evidence-based recommendations provide a standard way to plan for and make decisions about pregnancy testing in clinical trials, and also improve communications and transparency with trial participants," Calvert explained.

Source: Outsourcing-pharma.com

Drug Regulation and Pricing — Can Regulators Influence Affordability?

"Clinical drug development is generally an inefficient process. The cost of conducting clinical trials drives R&D spending, and much of the elaborate superstructure involved needs to be reassessed and could be pared down without harming participants. The EMA actively promotes better design and more efficient trial conduct and supports the efforts of the Clinical Trials Transformation Initiative, created by the Food and Drug Administration and Duke University, and other efforts to streamline trials."

Source: The New England Journal of Medicine

On the path to a science of patient input

"Some of the first formal efforts to outline the science of patient input borrow, from software development, the use of frameworks to provide a logical structure for organizing information, identifying sources of the information, and suggesting ways it might be used and viewed by distinct parties… The Clinical Trials Transformation Initiative (CTTI) created perhaps the most recognizable tool, and its work has become a guidepost.”

For more information of CTTI's Patient Groups & Clinical Trials Project, click here.

Source: Science Translational Medicine

Clinical Trials Need More Subjects

CTTI is featured as a driver of action-oriented solutions in this Wall Street Journal article that explores the critical need for improved patient recruitment rates. “We want to create trials that everyone involved can champion, and that doctors can feel good about engaging their patients in,” says Jamie Roberts, senior clinical project manager for the CTTI Recruitment Project.

Source: Wall Street Journal

Throwing Your Hat in the Ring

CTTI participated in MediaplanetUSA’s Clinical Trials campaign, where associations and industry experts came together to spotlight the need for more clinical trial participants, to change the public perception and showcase why clinical trials are so important in helping those in need. The campaign was distributed within the centerfold of USA Today on December 18, 2015.

Source: MediaPlanet

CTTI Releases Recommendations and Tools to Maximize Engagement between Research Sponsors and Patient Groups

"In recent years there has been an increasing focus on patient engagement, centering on new opportunities for FDA to incorporate the patient perspective into its regulatory decision making. These discussions have resulted in Congress and FDA establishing new policies and programs... However, the public dialogue has largely left out the opportunities for meaningful engagement between patients and research sponsors (academia and the medical product developers). That changed in 2014, when Clinical Trials Transformation Initiative (CTTI) initiated the Patient Groups & Clinical Trials (PGCT) Project. "

Source: FDA Law Blog

Make QbD A Part Of Your Clinical Trial Process

On CTTI's Quality by Design work: “Those principles were tested and refined through a series of workshops,” says Glessner. “I can’t speak highly enough about the power of those workshops. They actually involved putting materials into individual’s hands and testing them. Then after a period of time CTTI wanted to know whether the workshops were effective, and to determine that approximately 20 individuals were interviewed. These were deep, detailed interviews asking participants what they were able to take away from the workshops, what they were able to apply in their own businesses, and what problems continued to be a struggle for them.”

Source: Clinical Leader

Mobile technologies and clinical trials, a chance for a change

"In the words of Doctor Hans-Georg Eichler, Senior Medical Officer at the European Medicines Agency (EMA): 'We understand that trials as we do them today are not sustainable, they're expensive, they're inefficient, they take too long-patients complain why they have to wait so long for new medicines-and they're very bureaucratic.' EMA is part of the Clinical Trials Transformation Initiative (CTTI), established by the FDA and Duke University (Durham, USA), that aims to improve the quality and efficiency of trials."

Source: Mobile Health Global

Director's Corner Podcast

“We've been working [for] the past many years on trying to reform the clinical trial system in both the United States and worldwide because clinical trials are very resource wasteful in a sense… We're also working with the… Clinical Trials Transformation Initiative, to bite off different pieces of the current trial conduct and design and re-design those, and I think we've made significant progress there.”

Source: FDA

Insider Insights

“One of our biggest successes is [the] forum we created, in which there is trust for open dialogue… This atmosphere allows us to have all the stakeholders in clinical trials involved in being part of the solutions.” –Pamela Tenaerts, M.D.

Source: CenterWatch

FDA's Margaret Hamburg: Angle on Patient Engagement and Regulatory Systems Reform

“We think that there is a lot of merit in supporting improvements in the clinical trial infrastructure itself. The Clinical Trials Transformation Initiative has contributed so much in terms of innovative trial design, as it is working on establishing centralized IRBs for multicentered trials, which is an important advancement.”

Source: Applied Clinical Trials

Call to Action

“FDA’s active participation in partnerships like the Biomarkers Consortium, the Critical Path Initiative, and the Clinical Trials Transformation Initiative is critically important. What has the agency learned from these partnerships, and have officials taken necessary steps to implement new data as broadly and consistently as possible? Much progress remains until efficient trials with flexible designs aided by innovative technologies are no longer the exception to the rule.”

Source: 21st Century Cures